Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers
Purpose:
Shallow whole-genome sequencing (sWGS) can detect copy-number (CN) aberrations. In high-grade serous ovarian cancer (HGSOC) sWGS identified CN signatures such as homologous recombination deficiency (HRD) to direct therapy. We applied sWGS with targeted sequencing to p53abn endometrial cancers to identify additional prognostic stratification and therapeutic opportunities.
Experimental Design:
sWGS and targeted panel sequencing was performed on formalin-fixed, paraffin-embedded p53abn endometrial cancers. CN alterations, mutational data and CN signatures were derived, and associations to clinicopathologic and outcomes data were assessed.
Results:
In 187 p53abn endometrial cancers, 5 distinct CN signatures were identified. Signature 5 was associated with BRCA1/2 CN loss with features similar to HGSOC HRD signature. Twenty-two percent of potential HRD cases were identified, 35 patients with signature 5, and 8 patients with BRCA1/2 somatic mutations. Signatures 3 and 4 were associated with a high ploidy state, and CCNE1, ERBB2, and MYC amplifications, with mutations in PIK3CA enriched in signature 3. We observed improved overall survival (OS) for patients with signature 2 and worse OS for signatures 1 and 3. Twenty-eight percent of patients had CCNE1 amplification and this subset was enriched with carcinosarcoma histotype. Thirty-four percent of patients, across all histotypes, had ERBB2 amplification and/or HER2 overexpression on IHC, which was associated with worse outcomes. Mutations in PPP2R1A (29%) and FBXW7 (16%) were among the top 5 most common mutations.
Conclusions:
sWGS and targeted sequencing identified therapeutic opportunities in 75% of patients with p53abn endometrial cancer. Further research is needed to determine the efficacy of treatments targeting these identified pathways within p53abn endometrial cancers.
Top-30
Journals
|
1
|
|
|
Virchows Archiv
1 publication, 10%
|
|
|
Surgical and Experimental Pathology
1 publication, 10%
|
|
|
Cancers
1 publication, 10%
|
|
|
Journal of Pathology
1 publication, 10%
|
|
|
Current Oncology
1 publication, 10%
|
|
|
American Journal of Clinical Pathology
1 publication, 10%
|
|
|
npj Precision Oncology
1 publication, 10%
|
|
|
Biomarker Research
1 publication, 10%
|
|
|
British Journal of Cancer
1 publication, 10%
|
|
|
Modern Pathology
1 publication, 10%
|
|
|
1
|
Publishers
|
1
2
3
4
5
|
|
|
Springer Nature
5 publications, 50%
|
|
|
MDPI
2 publications, 20%
|
|
|
Wiley
1 publication, 10%
|
|
|
Oxford University Press
1 publication, 10%
|
|
|
Elsevier
1 publication, 10%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.